<DOC>
	<DOCNO>NCT00493818</DOCNO>
	<brief_summary>This study first time human , Phase I , open-label study determine recommend dos schedule , base maximum tolerated dos biologically active dos , AKT inhibitor GSK690693 .</brief_summary>
	<brief_title>Open-label Study Investigate Safety , Tolerability , PK , Pharmacodynamics AKT Inhibitor GSK690693</brief_title>
	<detailed_description />
	<criteria>Confirmed diagnosis solid tumor malignancy lymphoma responsive standard therapy approve therapy Female patient childbearing potential must willing abstain intercourse 2 week prior administration first dose study medication 28 day final dose study medication willing consistently correctly use acceptable method birth control . Prior anticancer therapy within prior 28 day . History diabetes . Coronary artery disease/myocardial infarction , acute coronary syndrome within past 6 month . Use theophylline warfarin within 14 day prior first dose study drug . Current use oral corticosteroid ( note : Inhaled corticosteroid permit . ) Participation investigational study within prior 28 day . Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK690693 ,</keyword>
	<keyword>Solid Tumors ,</keyword>
	<keyword>Lymphoma ,</keyword>
	<keyword>AKT</keyword>
</DOC>